BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M)
Form 10-Q / 10-K Income Taxes Note (XBRL)
Latest, Q2 2026
26.1
Period ended Jun 30, 2026
Change on a year earlier
+21.4%
21.5 in Q2 2025
History
38 quarters
Since Q4 2015
Sources
35
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 26.1 | +21.4% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 28.5 | +61.9% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 27.8 | +61.6% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 22 | +25.0% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 21.5 | +36.1% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 17.6 | +18.1% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 17.2 | +20.3% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 17.6 | +26.6% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 15.8 | +26.4% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 14.9 | +24.2% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 14.3 | +23.3% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 13.9 | +9.4% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 12.5 | +5.9% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 12 | +11.1% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 11.6 | +17.2% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 12.7 | +39.6% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 11.8 | +42.2% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 10.8 | +40.3% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 9.90 | +39.4% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 9.10 | +40.0% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 8.30 | +43.1% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 7.70 | +54.0% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 7.10 | +54.3% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2020 | Sep 30, 2020 | 6.50 | +97.0% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 5.80 | +100.0% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 5 | +92.3% | Form 10-Q (filed 2020-05-11) ↗ |
| Q4 2019 | Dec 31, 2019 | 4.60 | +100.0% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2019 | Sep 30, 2019 | 3.30 | +73.7% | Form 10-Q (filed 2019-11-12) ↗ |
| Q2 2019 | Jun 30, 2019 | 2.90 | +81.2% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 2.60 | +116.7% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 2.30 | +155.6% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2018 | Sep 30, 2018 | 1.90 | +216.7% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 1.60 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 1.20 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 0.90 | +800.0% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2017 | Sep 30, 2017 | 0.60 | – | 10-Q FY2017 (XBRL) ↗ |
| Q4 2016 | Dec 31, 2016 | 0.10 | – | Form 10-K (filed 2020-03-02) ↗ |
| Q4 2015 | Dec 31, 2015 | 0 | – | Form 10-K (filed 2019-02-28) ↗ |
Breakdown
What makes up unrecognized tax benefits (utb) — ending balance ($m)
- UTB Additions — Current Year Tax Positions ($M)–
- UTB Additions — Prior Year Tax Positions ($M)–
- UTB Reductions — Prior Year Tax Positions ($M)–
- UTB Reductions — Lapse of Statute of Limitations ($M)–
- Deferred Income Tax Liabilities, Net ($M)57.4 · Q2 2026
- Deferred Tax Assets Valuation Allowance ($M)–
- Effective Income Tax Rate (%)–
- Income Taxes Paid, Net ($M)70.6 · Q2 2026
- Noncurrent Value-Added Tax (VAT) Receivable ($M)3.80 · Q2 2026
- PRC Subsidiaries Restricted Net Assets ($M)–
Cite this data
StockData. (2026). BeOne Medicines Unrecognized Tax Benefits (UTB) — Ending Balance ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/utb_total
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.